Allarity Therapeutics, Inc.
Every calculator, already run for ALLR
Open the full toolkit →You have the numbers on ALLR. Get the argument.
A written report on which of these readings actually decide the outcome for Allarity Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
1 analysts covering ALLROwnership & short interest
Insider Trading Activity for ALLR
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemot…
ALLR — frequently asked
Is ALLR a buy right now?
Wall Street's consensus rating on Allarity Therapeutics, Inc. is Strong Buy across 1 analysts, with a mean price target of $11.00 (+1036% vs. the current $0.97). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare Allarity Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Allarity Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ALLR research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Allarity Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.